These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14592696)

  • 1. Characterization of solid-state forms of celecoxib.
    Chawla G; Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
    Eur J Pharm Sci; 2003 Nov; 20(3):305-17. PubMed ID: 14592696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of solid-state forms of mebendazole.
    Kumar S; Chawla G; Sobhia ME; Bansal AK
    Pharmazie; 2008 Feb; 63(2):136-43. PubMed ID: 18380400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of processing on Celecoxib and its solvates.
    Chawla G; Bansal AK
    Pharm Dev Technol; 2004 Nov; 9(4):419-33. PubMed ID: 15581078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexation of celecoxib with beta-cyclodextrin: characterization of the interaction in solution and in solid state.
    Sinha VR; Anitha R; Ghosh S; Nanda A; Kumria R
    J Pharm Sci; 2005 Mar; 94(3):676-87. PubMed ID: 15668949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Devitrification of amorphous celecoxib.
    Gupta P; Bansal AK
    AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties.
    Gupta VR; Mutalik S; Patel MM; Jani GK
    Acta Pharm; 2007 Jun; 57(2):173-84. PubMed ID: 17507314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-line solid state prediction during pharmaceutical hot-melt extrusion in a 12 mm twin screw extruder using Raman spectroscopy.
    Saerens L; Ghanam D; Raemdonck C; Francois K; Manz J; Krüger R; Krüger S; Vervaet C; Remon JP; De Beer T
    Eur J Pharm Biopharm; 2014 Aug; 87(3):606-15. PubMed ID: 24657540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential molecular interactions between the crystalline and the amorphous phases of celecoxib.
    Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
    J Pharm Pharmacol; 2005 Oct; 57(10):1271-8. PubMed ID: 16259755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V; Perioli L; Marmottini F; Rossi C
    Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility.
    Gupta P; Bansal AK
    Pharmazie; 2005 Nov; 60(11):830-6. PubMed ID: 16320944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
    Ha ES; Choo GH; Baek IH; Kim MS
    Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
    Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
    Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion.
    Albers J; Alles R; Matthée K; Knop K; Nahrup JS; Kleinebudde P
    Eur J Pharm Biopharm; 2009 Feb; 71(2):387-94. PubMed ID: 18951978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a novel polymorphic form of celecoxib.
    Lu GW; Hawley M; Smith M; Geiger BM; Pfund W
    J Pharm Sci; 2006 Feb; 95(2):305-17. PubMed ID: 16369929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation and evaluation of pharmaceutical solvates of Atorvastatin calcium by thermoanalytical and spectroscopic studies.
    Chadha R; Kuhad A; Arora P; Kishor S
    Chem Cent J; 2012 Oct; 6(1):114. PubMed ID: 23039933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques.
    Homayouni A; Sadeghi F; Varshosaz J; Afrasiabi Garekani H; Nokhodchi A
    Colloids Surf B Biointerfaces; 2014 Oct; 122():591-600. PubMed ID: 25124835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of surfactants on the crystal growth of amorphous celecoxib.
    Mosquera-Giraldo LI; Trasi NS; Taylor LS
    Int J Pharm; 2014 Jan; 461(1-2):251-7. PubMed ID: 24333451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on mechanism for amorphous drug stabilization using gelucire 50/13.
    Shimpi SL; Mahadik KR; Paradkar AR
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):937-42. PubMed ID: 19721253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.
    Gupta P; Kakumanu VK; Bansal AK
    Pharm Res; 2004 Oct; 21(10):1762-9. PubMed ID: 15553220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and thermodynamic aspects of solubility advantage from solid dispersions.
    Bansal SS; Kaushal AM; Bansal AK
    Mol Pharm; 2007; 4(5):794-802. PubMed ID: 17867643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.